Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Paul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn...
https://pubmed.ncbi.nlm.nih.gov/36084320/Actively Recruiting
Phase 2
Phase 3
Age: 1Year - 18Years
All Genders
ID06882057
Chinese Childrens Cancer Group 2025 Study on Blinatumomab Treatment for Newly Diagnosed Low-Risk Pediatric B-cell Acute Lymphoblastic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-26
3000
Participants Needed
27
Research Sites
178 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a new treatment plan called CCCG-ALL2025 for children with newly diagnosed low-risk B-cell acute lymphoblastic leukemia ALL. This plan builds on previous protocols and uses blinatumomab Blina-14 as an early intensification treatment after initial therapy, regardless of the patients measurable residual disease MRD status. The study aims to compare the effectiveness of chemotherapy combined with Blina-14 to previous treatments, with adjustments to maintenance therapy based on deep remission measured by next-generation sequencing Ig-NGS MRD.
CONDITIONS
Brief Title
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Research Team
X
Xiaofan Zhu, MD
J
Jingliao Zhang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here